PriceTargets.com logo

Sareum - SAR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 304
  • Forecasted Upside: 1,180.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 23.75 As of 04/19/2024 01:00 AM ET
▼ -3 (-11.21%)

This chart shows the closing price for SAR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sareum Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAR

Analyst Price Target is GBX 304
▲ +1,180.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sareum in the last 3 months. The average price target is GBX 304, with a high forecast of GBX 304 and a low forecast of GBX 304. The average price target represents a 1,180.00% upside from the last price of GBX 23.75.

This chart shows the closing price for SAR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Sareum. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/6/2023Peel HuntReiterated RatingBuyGBX 304
(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sareum logo
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancerandcancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: GBX 23.75
Low: 22
High: 28.75

50 Day Range

MA: GBX 24.81
Low: 10.25
High: 43.50

52 Week Range

Now: GBX 23.75
Low: 10
High: 149

Volume

6,403,299 shs

Average Volume

894,566 shs

Market Capitalization

£17.04 million

P/E Ratio

N/A

Dividend Yield

1.10%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sareum?

The following Wall Street research analysts have issued reports on Sareum in the last year: Peel Hunt.
View the latest analyst ratings for SAR.

What is the current price target for Sareum?

1 Wall Street analysts have set twelve-month price targets for Sareum in the last year. Their average twelve-month price target is GBX 304, suggesting a possible upside of 1,180.0%. Peel Hunt has the highest price target set, predicting SAR will reach GBX 304 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 304 for Sareum in the next year.
View the latest price targets for SAR.

What is the current consensus analyst rating for Sareum?

Sareum currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SAR will outperform the market and that investors should add to their positions of Sareum.
View the latest ratings for SAR.

What other companies compete with Sareum?

Other companies that are similar to Sareum include Synairgen, Realm Therapeutics, ImmuPharma, BiVictriX Therapeutics and NetScientific. Learn More about companies similar to Sareum.

How do I contact Sareum's investor relations team?

Sareum's physical mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company's listed phone number is +44-1223-497700. The official website for Sareum is www.sareum.co.uk. Learn More about contacing Sareum investor relations.